British Pharmaceutical giant AstraZeneca made a statement on Friday that Alexion, a subsidiary of AstraZeneca had agreed to buy US Pharmaceutical Pfizer’s newly established gene-based therapy portfolio for $1 billion dollars.
The head of research and development of the British subsidiary unit Alexion, Sharon Barr would lead the role.
Mene Pangalos, head of AstraZeneca, is the key figure developing the Covid-19 vaccine.
In 2021, AstraZeneca closed the deal to buy Alexion at $39 billion dollars from Pfizer.
Together Alexion and AstraZeneca shift their focus to complex viruses and to develop more effective medicine.
Gene-based therapy like the AVV capsid gives rise to a more enhanced form of therapy-based treatments.
Last year, AstraZeneca acquired a number of pharma companies including LogicBio Therapeutics for $68 million dollars.
AstraZeneca looking to buy another US drugmaker CinCor Pharma for $1.8 billion dollars to increase its sales.
AstraZeneca shows reslience in cancer related durgs boosting its sales into a new high’s after the end of COVID contengency.
